[
  {
    "ts": null,
    "headline": "Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia",
    "summary": "WILMINGTON, Del., December 08, 2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET",
    "url": "https://finnhub.io/api/news?id=96199cd7f1bb1d69633c561d94addae8fbe6d6faf48dbabd18e3a84205f4cd95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765229400,
      "headline": "Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia",
      "id": 137738219,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 08, 2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET",
      "url": "https://finnhub.io/api/news?id=96199cd7f1bb1d69633c561d94addae8fbe6d6faf48dbabd18e3a84205f4cd95"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status",
    "summary": "INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.",
    "url": "https://finnhub.io/api/news?id=e47a63b5a1f1cdeacf69c27e68f1a70d5d07caeef779ca839fe83ef958c08a2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765207800,
      "headline": "Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status",
      "id": 137732897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.",
      "url": "https://finnhub.io/api/news?id=e47a63b5a1f1cdeacf69c27e68f1a70d5d07caeef779ca839fe83ef958c08a2d"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
    "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.",
    "url": "https://finnhub.io/api/news?id=c1cce4e832bb2b027fa3899ea203b0900842de3562b16bfc8fa0d0b0f74321a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765204951,
      "headline": "Incyte Stock Falls Despite FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug",
      "id": 137732898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock fell from near five-year highs.",
      "url": "https://finnhub.io/api/news?id=c1cce4e832bb2b027fa3899ea203b0900842de3562b16bfc8fa0d0b0f74321a3"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH - Slideshow",
    "summary": "2025-12-08. The following slide deck was published by Incyte Corporation in conjunction with this event.",
    "url": "https://finnhub.io/api/news?id=a4e5fedd1790aca9936c4e8a2922ee77a1e2ea252501197e4bf0086b4697a0f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765182681,
      "headline": "Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH - Slideshow",
      "id": 137731133,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "2025-12-08. The following slide deck was published by Incyte Corporation in conjunction with this event.",
      "url": "https://finnhub.io/api/news?id=a4e5fedd1790aca9936c4e8a2922ee77a1e2ea252501197e4bf0086b4697a0f0"
    }
  }
]